Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.39 |
| ▸ | RXRG | P48443 | 1/20 | 0.39 |
| ▸ | XDH | P47989 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 2/20 | 0.33 |
| ▸ | KIF11 | P52732 | 2/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.32 |
| ▸ | AR | P10275 | 2/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.31 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | METAP2 | P50579 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19903696 | 0.99 | RXRA (0.38) | RXRARXRGXDHPGRKIF11 | |
| SCHEMBL20617117 | 0.98 | RXRA (0.39) | RXRARXRGXDHPGRKIF11 | |
| SCHEMBL22822162 | 0.95 | KIF11 (0.39) | RXRARXRGXDHKIF11PDPK1 | |
| SCHEMBL22564190 | 0.95 | RXRA (0.40) | RXRARXRGXDHPGRKIF11 | |
| SCHEMBL22822580 | 0.95 | RXRA (0.42) | RXRARXRGXDHPGRKIF11 | |
| SCHEMBL19918006 | 0.94 | PTPN5 (0.39) | RXRARXRGXDHPGRGRIN1 | |
| SCHEMBL22822479 | 0.94 | PTPN5 (0.39) | RXRARXRGXDHPGRGRIN1 | |
| SCHEMBL22822680 | 0.94 | RXRA (0.39) | RXRARXRGXDHPGRKIF11 | |
| SCHEMBL20617037 | 0.94 | RXRA (0.39) | RXRARXRGXDHPGRKIF11 | |
| SCHEMBL19917824 | 0.94 | KIF11 (0.39) | RXRARXRGKIF11PDPK1AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11021473-B2 | Organic molecules for use in organic optoelectronic devices | CYNORA GMBH (DE) | 2021-06-01 | — | — | US | disclosed |
| US-20200399256-A1 | ORGANIC MOLECULES FOR USE IN ORGANIC OPTOELECTRONIC DEVICES | SAMSUNG DISPLAY CO., LTD. (KR) | 2020-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11021473-B2 | Organic molecules for use in organic optoelectronic devices | OR10J3, OR51E2, OCIAD2 | RXRA 3552/4885RXRG 3138/4885XDH 430/4885 |
| US-20200399256-A1 | ORGANIC MOLECULES FOR USE IN ORGANIC OPTOELECTRONIC DEVICES | OR10J3, ORC3, AOC3 | RXRA 3876/4885RXRG 3543/4885XDH 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.